Therapeutic options and emerging alternatives for multidrug resistant staphylococcal infections.

abstract：:Parkinson's disease (PD) is a common neurodegenerative disorder characterized by cardinal features of tremor, bradykinesia, rigidity and postural instability. In addition to the motor symptoms patients experience cognitive decline eventually resulting in severe disability. Pathologically PD is characterized by neurode...

journal_title：Current pharmaceutical design

authors： Thomas M,Le WD

更新日期：2004-01-01 00:00:00

abstract：:ATP-binding cassette (ABC) transporters are a huge family of ATP-dependent transmembrane proteins whose main function is exporting or importing substances or molecules through the cell membranes, plasma cell membrane, or inner membranes in organelles. They fulfill these functions by maintaining cell integrity, metabol...

journal_title：Current pharmaceutical design

authors： Benadiba M,Maor Y

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide directly related to the progressive increase in overweight and obesity. The accumulation of lipids in patients with NAFLD contributes to the development of insulin resistance, inflammatory response a...

journal_title：Current pharmaceutical design

authors： Tejada S,Capó X,Mascaró CM,Monserrat-Mesquida M,Quetglas-Llabrés MM,Pons A,Tur JA,Sureda A

更新日期：2020-04-17 00:00:00

abstract：:Sex-dependent differences are frequently observed in the biological and behavioural effects of substances of abuse, including cannabis. We recently demonstrated a modulating effect of sex and oestrous cycle on cannabinoid-taking and seeking behaviours. Here, we investigated the influence of sex and oestrogen in the re...

journal_title：Current pharmaceutical design

authors： Castelli MP,Fadda P,Casu A,Spano MS,Casti A,Fratta W,Fattore L

更新日期：2014-01-01 00:00:00

abstract：:Tocotrienols, components belonging to vitamin E members, are used as potent therapeutics in the treatment of several diseases. Recent studies suggested tocotrienol to have better activity in many situations compared to tocopherols. Tocotrienols have been shown to lower the atherogenic apolipoprotein B and lipoprotein ...

journal_title：Current pharmaceutical design

authors： Catalgol B,Batirel S,Ozer NK

更新日期：2011-01-01 00:00:00

abstract：:Alzheimer's disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly accounts for clinical dementia. Inflammation plays a key role in AD and dissecting the genetics of inflammation may provide an answer to the possible treatment. Hence, the better understanding of diffe...

journal_title：Current pharmaceutical design

authors： Balistreri CR,Grimaldi MP,Chiappelli M,Licastro F,Castiglia L,Listì F,Vasto S,Lio D,Caruso C,Candore G

更新日期：2008-01-01 00:00:00

abstract：:The last quarter of a century has witnessed remarkable progress in the understanding of phosphoinositide 3-kinases (PI3K) signalling and their involvement in different diseases such as cancer, diabetes and inflammation. Nevertheless, many questions remain open and among these the role of genetic and epigenetic regulat...

journal_title：Current pharmaceutical design

authors： Fyffe C,Buus R,Falasca M

更新日期：2013-01-01 00:00:00

abstract：:Cathepsin K, a cysteine protease of the papain family, was identified by sequencing complementary DNA libraries derived from osteoclasts. Cathepsin K can cleave bone proteins such as Type I collagen, osteopontin, and osteonectin. The localization and maturation of cathepsin K in activated osteoclasts have been charact...

journal_title：Current pharmaceutical design

authors： Yamashita DS,Dodds RA

更新日期：2000-01-01 00:00:00

abstract：:During the last two decades, the studies on ubiquitination in regulating transcription factor NF-κB activation have elucidated the expanding role of ubiquitination in modulating cellular events by non-proteolytic mechanisms, as well as by proteasomal degradation. The significance of ubiquitination has also been recogn...

journal_title：Current pharmaceutical design

authors： Wu ZH,Shi Y

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:A substantial part of literature has been centered on sex differences in the clinical aspects of ischemic heart disease (IHD). Many reports have documented differences in the presentation and risk profile between women and men. Such differences drive sex-related inequalities in the referral and treatment of ...

journal_title：Current pharmaceutical design

authors： Cenko E,Bugiardini R

更新日期：2016-01-01 00:00:00

abstract：:Reduction strategies of blood pressure, as a modifiable cardiovascular risk, are currently based on office assessment of brachial artery blood pressure. However, antihypertensive treatment based on brachial BP values reduces cardiovascular risk but cannot completely reverse the hypertension-induced risk of morbidity e...

journal_title：Current pharmaceutical design

authors： Rinaldi ER,Yannoutsos A,Borghi C,Safar ME,Blacher J

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Cardiac resynchronization therapy (CRT) is a valuable intracardiac device--based treatment option for a subgroup of patients with advanced heart failure (HF) and QRS prolongation. However, still a significant proportion of patients do not benefit from CRT implantation, labeled as non-responders. OBJECTIVES:...

journal_title：Current pharmaceutical design

authors： Debska-Kozlowska A,Ksiazczyk M,Warchol I,Lubinski A

更新日期：2019-01-01 00:00:00

abstract：:There is a plausible role for cytokines, brain-derived neurotrophic factor (BDNF), and their interaction in major depressive disorder's (MDD) etiology. This review includes (i) briefly defining cytokines, (ii) a discussion of theories for why they may affect brain function, (iii) cross-sectional associations between c...

journal_title：Current pharmaceutical design

authors： Lotrich F

更新日期：2012-01-01 00:00:00

abstract：:Over the last decade, much was learned about the biology of several types of stem and progenitor cells. It has become apparent that various cell sources may have the capacity to promote cardiomyogenesis and new blood vessel formation through different mechanisms, forming the rationale for cell-based therapy in patient...

journal_title：Current pharmaceutical design

authors： Rodrigo SF,Ramshorst Jv,Beeres SL,Bax JJ,Schalij MJ,Atsma DE

更新日期：2011-10-01 00:00:00

abstract：:Apoptosis is a regulated process leading to cell death, which is implicated both in normal development and in various pathologies including heart failure, stroke and neurodegenerative diseases. Caspase-3, a key enzyme of the apoptotic pathway, is considered as a major target for the treatment of abnormal cell death. M...

journal_title：Current pharmaceutical design

authors： Seaborn T,Masmoudi-Kouli O,Fournier A,Vaudry H,Vaudry D

更新日期：2011-01-01 00:00:00

abstract：:Atrial fibrillation (AF) is the most common sustained rhythm disturbance, increasing prevalence with age, in particular in patients with cardiovascular disease. On the other hand, a subset of patients with AF being <60 years old and no evidence of underlying cardiovascular disease, and laboratory tests including thyro...

journal_title：Current pharmaceutical design

authors： Tello-Montoliu A,Hernández-Romero D,Sanchez-Martínez M,Valdes M,Marín F

更新日期：2015-01-01 00:00:00

abstract：:Abnormal regulation of the ubiquitin-proteasome system (UPS) has been known to be involved in the pathogenesis of a variety of human diseases. A number of studies have focused on the identification of small modifiers for the UPS. Even though the proteasome inhibitor Bortezomib (Velcade®) has been approved for the ther...

journal_title：Current pharmaceutical design

authors： Lim KH,Baek KH

更新日期：2013-01-01 00:00:00

abstract：:Quinolines are nitrogen heterocyclic compounds ubiquitous in nature and largely used as a structural component of dyes, solvent for resins, terpenes as well as during the production of several other chemical stuffs, including pesticides. Quinolines, such as quinine and chloroquine, exhibit various pharmacological prop...

journal_title：Current pharmaceutical design

authors： da Gama ANS,de Nazaré Correia Soeiro M

更新日期：2020-10-06 00:00:00

abstract：:With a 2030 projection of 23.6 million deaths per year the prevalence and severity of cardiovascular disease is at an astounding high. Thus, a definitive need for the identification of novel compounds with potential to prevent or treat the disease and associated states. Moreover, there is also an ever-increasing need ...

journal_title：Current pharmaceutical design

authors： Houacine C,Khan I,Yousaf SS

更新日期：2020-09-09 00:00:00

abstract：:Age-associated cognitive decline and dementia are conditions in which there is deterioration in memory, thinking, and behavior, with profound effects on the ability to perform everyday activities and well-being. Even if dementia mainly affects older persons, it is not a normal part of aging. Alzheimer's disease accoun...

journal_title：Current pharmaceutical design

authors： Dominguez LJ,Barbagallo M

更新日期：2016-01-01 00:00:00

abstract：:MicroRNAs (miRNAs) play a vital role in the onset and development of many diseases, including cancers. Emerging evidence shows that numerous miRNAs have the potential to be used as diagnostic biomarkers for cancers, and miRNA-based therapy may be a promising therapy for the treatment of malignant neoplasm. MicroRNA-14...

journal_title：Current pharmaceutical design

authors： Ma Y,Cao X,Shi G,Shi T

更新日期：2020-10-28 00:00:00

abstract：BACKGROUND:Lipid nanoparticles have attracted increased degree of scientific and commercial attention in the last decade. The lipidic nanoparticles have emerged as a potential alternative to other nano-scale systems due to their various advantages over them and also due to overcoming the shortcomings of the already ava...

journal_title：Current pharmaceutical design

authors： Pathak K,Shankar R,Joshi M

更新日期：2017-11-21 00:00:00

abstract：:Phosphodiesterase 2 (PDE2) is a ubiquitous enzyme whose major role is to hydrolyze the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). In the central nervous system, pharmacological inhibition of PDE2 results in boosted cAMP and/or cGMP signaling, which is r...

journal_title：Current pharmaceutical design

authors： Zhang C,Yu Y,Ruan L,Wang C,Pan J,Klabnik J,Lueptow L,Zhang HT,O'Donnell JM,Xu Y

更新日期：2015-01-01 00:00:00

abstract：:Atherosclerosis is an inflammatory vascular disease that is characterized by progressive accumulation of cholesterol in the arterial walls and it is a major cause of cardiovascular disease. Issues related to the side effects of synthetic drugs have in recent times, led to the misuse of drugs, a lack of patient consult...

journal_title：Current pharmaceutical design

authors： Gholipour S,Sewell RDE,Lorigooini Z,Rafieian-Kopaei M

更新日期：2018-01-01 00:00:00

abstract：:The deregulated proteolysis is associated with various diseases in humans. Proteases are commonly regarded as the therapeutic targets. Almost one-third of all proteolytic enzymes in humans are serine proteases. This work provides a brief characteristic of the proteinaceous natural inhibitors, mostly of serine protease...

journal_title：Current pharmaceutical design

authors： Debowski D

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Progression of aortic valve calcifications (AVC) leads to aortic valve stenosis (AS). Importantly, the AVC degree has a great impact on AS progression, treatment selection and outcomes. Methods of AVC assessment do not provide accurate quantitative evaluation and analysis of calcium distribution and depositi...

journal_title：Current pharmaceutical design

authors： Wiktorowicz A,Wit A,Dziewierz A,Rzeszutko L,Dudek D,Kleczynski P

更新日期：2019-01-01 00:00:00

abstract：:We conducted a systematic review on resting state cerebral blood flow activities found in first-episode psychosis (FEP) and during acute effects of cannabinoids and opioids, mental states that can be profoundly different from normal functioning. The main goal was to identify connections of cerebral blood flow measure ...

journal_title：Current pharmaceutical design

authors： Denier N,Walter M,Bendfeldt K,Lang U,Borgwardt S

更新日期：2012-01-01 00:00:00

abstract：:The hypothesis that the interaction of agouti-related protein (AGRP) and the melanocortin-4 receptor (MC4R) modulates feeding behavior in humans has stimulated the synthesis of conformationally constrained peptides, peptoids and small molecules in efforts to identify novel compounds that can potentially be used in the...

journal_title：Current pharmaceutical design

authors： Wang X,Richards NG

更新日期：2005-01-01 00:00:00

abstract：:DNA methylation, a major regulator of epigenetic modifications has been shown to alter the expression of genes that are involved in aspects of glucose metabolism such as glucose intolerance, insulin resistance, β-cell dysfunction and other conditions, and it ultimately leads to the pathogenesis of type 2 diabetes mell...

journal_title：Current pharmaceutical design

authors： Alam F,Islam MA,Gan SH,Mohamed M,Sasongko TH

更新日期：2016-01-01 00:00:00

abstract：:Free energy perturbation (FEP) theory coupled to molecular dynamics (MD) or Monte Carlo (MC) statistical mechanics offers a theoretically precise method for determining the free energy differences of related biological inhibitors. Traditionally requiring extensive computational resources and expertise, it is only rece...

journal_title：Current pharmaceutical design

authors： Acevedo O,Ambrose Z,Flaherty PT,Aamer H,Jain P,Sambasivarao SV

更新日期：2012-01-01 00:00:00